SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)

Autor: Retz, Margitta, Bedke, Jens, Bögemann, Martin, Grimm, Marc-Oliver, Zimmermann, Uwe, Müller, Lothar, Leiber, Christian, Teber, Dogu, Wirth, Manfred, Bolenz, Christian, van Alphen, Robbert, De Santis, Maria, Beeker, Aart, Lehmann, Jan, Indorf, Martin, Frank, Melanie, Bokemeyer, Carsten, Gschwend, Jürgen E.
Zdroj: In European Journal of Cancer January 2019 107:37-45
Databáze: ScienceDirect
Externí odkaz: